兴齐眼药: 第五届董事会第九次会议决议公告

Core Viewpoint The company, Shenyang Xingqi Eye Pharmaceutical Co., Ltd., has approved a plan to issue A-shares to specific investors, aiming to raise up to 850 million yuan for various projects, subject to shareholder approval and regulatory compliance. Group 1: Board Meeting and Resolutions - The board meeting was conducted via electronic means, and all members were notified of the meeting details [1] - The board approved the proposal for the company to issue A-shares to specific investors, confirming compliance with relevant laws and regulations [2][3] - The voting results for all resolutions were unanimous, with 9 votes in favor and no opposition [1][2][3] Group 2: Issuance Details - The issuance will consist of domestic A-shares with a par value of 1 yuan each, targeting no more than 35 specific investors [2][3] - The pricing will be set at no less than 80% of the average trading price over the 20 trading days prior to the pricing date [4] - The total amount raised from the issuance will not exceed 850 million yuan, with the number of shares issued capped at 30% of the total shares before the issuance [5][6] Group 3: Fund Utilization and Project Investment - The net proceeds from the issuance will be fully invested in specific projects, with a total investment amounting to 1.184 billion yuan, of which 850 million yuan will come from the issuance [6][7] - If the actual funds raised are less than planned, the company will adjust the investment amounts based on project importance and urgency [7] Group 4: Shareholder Rights and Limitations - Shares acquired through this issuance will be subject to a six-month lock-up period post-issuance [6] - The company's retained earnings will be shared proportionally among existing and new shareholders after the issuance [7] Group 5: Future Steps and Authorizations - The board will seek authorization from shareholders to manage the issuance process, including adjustments based on market conditions and regulatory requirements [12][13] - A temporary shareholder meeting is scheduled for June 13, 2025, to discuss the issuance and other related matters [15]